As of late October, healthcare's newest unicorn - Butterfly Network - has begun shipping its ultrasound-on-a-chip system that a senior executive believes will alter the field of ultrasound forever.
Loxo's shares were up 65 percent on the news. The company won FDA accelerated approval on Nov. 26 for its tissue-agnostic cancer drug, Vitrakvi.
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
That the drug will only be given to patients shown through testing to harbor a genetic anomaly that increases the odds of a response makes its approval an important milestone in the evolution of value-based care.
An oncologist compared NTRK fusion patients to a needle in a haystack, but had some clues of how to find them. Still, drugs like Vitrakvi call for genomic sequencing of all cancer patients, he said.
The New England health system and the healthcare IT consulting firm have joined forces to launch baytechIT, which seeks to help medical practices, clinics and healthcare social services organizations meet their complicated IT needs.
Cigna competitors who have launched their own venture arms include Humana, Kaiser Permanente and UnitedHealthGroup's Optum division.
Dickon Waterfield discusses why Lantern's navigation works.
OCA Ventures is the newest investor in the New Haven, Connecticut-based startup, which has raised another $1 million in its Series A round of funding.
Interim data from the Phase I data show 77 percent overall response rate, including 74 percent confirmed responses.
Loxo's data highlight growing industry interest in so-called "basket" trials and drugs that targeted to genetic markers instead of tumor types.
In a letter to athenahealth's board of directors, Elliott Management Partner Jesse Cohn makes his firm's case for why the company would be better off as a private business.
How Apella leverages technology to increase OR efficiency.
The use of coupons and manufacturer buydowns is increasing as a way to offset what would otherwise be increasing costs borne by the patients, according to Murray Aitken, senior vice president and executive director of the IQVIA Institute for Human Data Science,
The idea is to give qualified injured employees an alternative to going to an emergency room as part of an effort to contain healthcare costs.
Butterfly Network previewed its Tele-Guidance technology at the American Institute of Ultrasound in Medicine (AIUM) Convention in New York City.
The acquisition not only reflects the interest in connecting insurance companies to PBMs but it also raises questions about what it could mean for drug prices in the future.
California insurance commissioner Dave Jones has launched an investigation into Aetna after its former medical director, Jay Ken Iinuma, said under oath that he never looked at patients' medical records when deciding whether to approve or deny claims.